Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank38
3Y CAGR-19.6%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-19.6%/yr
vs -13.8%/yr prior
Acceleration
-5.8pp
Decelerating
Percentile
P38
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 42.17% |
| 2024 | 25.43% |
| 2023 | 143.98% |
| 2022 | 81.18% |
| 2021 | 297.77% |
| 2020 | -78.75% |
| 2019 | 108.12% |
| 2018 | 147.01% |
| 2017 | 0.00% |